
    
      This is a retrospective cohort study of Thai octogenarians with NVAF. Patients who were
      prescribed with apixaban, dabigatran, edoxaban, rivaroxaban or warfarin from January 1, 2013,
      to December 31, 2018 were recruited. The primary efficacy was recurrent ischemic stroke or
      TIA in 90 days after initiating OACs. The secondary efficacy were recurrent ischemic stroke
      or TIA in 180 days after initiating OACs. While any bleeding complications were defied as
      primary safety outcomes. Continuous variables were compared using independent t test and
      MannWhitney U test, and categorical variables were compared using chi-square test or Fisher's
      exact test.
    
  